Physician profile
James N Cornwell
NPI 1669884987
$6,555.67
in general payments reported to CMS, 2019-2025
34 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $915 · 2021: $711 · 2022: $597 · 2023: $852 · 2024: $1,059 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,176.31 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $960.07 | 2019-2022 | |
| Glaxosmithkline, LLC. | $565.21 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corium, LLC | $451.05 | 2022-2025 | Azstarys, Azstarys |
| Pfizer INC. | $408.97 | 2019-2025 | |
| Abbvie INC. | $375.22 | 2021-2025 | Vraylar, Mavyret |
| Lilly USA, LLC | $297.59 | 2019-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $260.55 | 2019-2025 | Ozempic, Rybelsus |
| Alk-Abello, INC | $158.83 | 2023-2024 | Odactra, Ragwitek, Grastek |
| Astellas Pharma US INC | $148.00 | 2019-2025 | Veozah |
| Amgen INC. | $136.49 | 2022-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $77.90 | 2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $70.12 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $45.34 | 2025 | Zoryve |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.67 | 2024-2025 | Caplyta |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $36.43 | 2020-2022 | |
| Bioventus LLC | $30.41 | 2024-2025 | Durolane |
| Insulet Corporation | $25.35 | 2023 | Omnipod |
| Dexcom, INC. | $25.12 | 2025 | Dexcom G6 Transmitter |
| Genentech, INC. | $23.21 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $22.47 | 2025 | Zilretta |
| Pacira Therapeutics, INC. | $22.23 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.84 | 2022 | |
| Organon LLC | $20.68 | 2023 | Nexplanon |
| Abbott Laboratories | $18.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.52 | 2019 | |
| Pharmacosmos Therapeutics INC. | $17.44 | 2023 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $16.76 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.27 | 2025 | |
| Sunovion Pharmaceuticals INC. | $15.18 | 2020 | |
| Gilead Sciences, INC. | $14.51 | 2019 | |
| Electromed, INC. | $14.40 | 2025 | Smartvest |
| Biogen, INC. | $14.29 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cornwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.